-
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639 ·
Phase: Not specified ·
Ages: 14 Years to 37 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
NCT07187973 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226 ·
Phase: Phase 3 ·
Ages: 2 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, North Canton
-
A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
NCT06290401 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 13 Years to 21 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland, Columbus
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Ohio: Akron, Cincinnati, Cleveland, Columbus
-
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Columbus
-
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
NCT06941389 ·
Phase: Not specified ·
Ages: 3 Years to 20 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
NCT06919224 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Columbus
-
Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
NCT07177300 ·
Phase: Phase 4 ·
Ages: 6 Months and older ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
NCT04819841 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years to 50 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
HPC Offered for PRESERVE Expansion
NCT07145411 ·
Phase: Not specified ·
Ages: 12 Years to 80 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
NCT04093986 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
NCT06725550 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 14 Years to 80 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Integrative Training Program for Pediatric Sickle Cell Pain
NCT06691867 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 12 Years to 18 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
NCT06853158 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 14 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
NCT03587272 ·
Phase: Phase 2 ·
Ages: 2 Years to 25 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
NCT06385886 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Columbus
-
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849 ·
Phase: Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Columbus
-
Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)
NCT02824471 ·
Phase: Not specified ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
NCT07356050 ·
Phase: Not specified ·
Ages: 6 Months to 6 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
NCT06260891 ·
Phase: Phase 2 ·
Ages: 15 Years to 40 Years ·
Sex: All (male and female)
· Ohio: Cincinnati